

Pavel Katsel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1473747/publications.pdf>

Version: 2024-02-01

41
papers

3,136
citations

186265

28
h-index

302126

39
g-index

45
all docs

45
docs citations

45
times ranked

4974
citing authors

#	ARTICLE	IF	CITATIONS
1	PGC-1 β Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. Archives of Neurology, 2009, 66, 352-61.	4.5	323
2	The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Scientific Data, 2018, 5, 180185.	5.3	320
3	Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Medicine, 2016, 8, 104.	8.2	224
4	Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer's Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer's Disease?. Neurochemical Research, 2007, 32, 845-856.	3.3	213
5	Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. Schizophrenia Research, 2005, 79, 157-173.	2.0	204
6	Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. Science Advances, 2021, 7, .	10.3	137
7	FSH blockade improves cognition in mice with Alzheimer's disease. Nature, 2022, 603, 470-476.	27.8	131
8	Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease. Neuron, 2021, 109, 257-272.e14.	8.1	108
9	Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease. Molecular Neurodegeneration, 2017, 12, 82.	10.8	100
10	Molecular and Genetic Evidence for Abnormalities in the Nodes of Ranvier in Schizophrenia. Archives of General Psychiatry, 2012, 69, 7.	12.3	97
11	A System-Level Transcriptomic Analysis of Schizophrenia Using Postmortem Brain Tissue Samples. Archives of General Psychiatry, 2012, 69, 1205.	12.3	94
12	Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease. Nature Communications, 2020, 11, 3942.	12.8	94
13	Abnormal Indices of Cell Cycle Activity in Schizophrenia and their Potential Association with Oligodendrocytes. Neuropsychopharmacology, 2008, 33, 2993-3009.	5.4	90
14	Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. International Journal of Neuropsychopharmacology, 2007, 10, 565.	2.1	89
15	Astrocyte and Glutamate Markers in the Superficial, Deep, and White Matter Layers of the Anterior Cingulate Gyrus in Schizophrenia. Neuropsychopharmacology, 2011, 36, 1171-1177.	5.4	79
16	The Human Homolog of the QKI Gene Affected in the Severe Dysmyelination "Quaking" Mouse Phenotype: Downregulated in Multiple Brain Regions in Schizophrenia. American Journal of Psychiatry, 2006, 163, 1834-1837.	7.2	78
17	Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiology of Aging, 2009, 30, 561-573.	3.1	77
18	The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimer's and Dementia, 2015, 11, 1163-1170.	0.8	70

#	ARTICLE	IF	CITATIONS
19	Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. <i>Schizophrenia Research</i> , 2010, 120, 150-158.	2.0	64
20	Microvascular anomaly conditions in psychiatric disease. Schizophrenia – angiogenesis connection. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 327-339.	6.1	58
21	Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer’s disease at various cognitive stages. <i>Scientific Reports</i> , 2018, 8, 938.	3.3	51
22	Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals. <i>PLoS ONE</i> , 2009, 4, e7642.	2.5	50
23	Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. <i>Brain Research</i> , 2010, 1318, 167-177.	2.2	46
24	Cycle Checkpoint Abnormalities during Dementia: A Plausible Association with the Loss of Protection against Oxidative Stress in Alzheimer’s Disease. <i>PLoS ONE</i> , 2013, 8, e68361.	2.5	46
25	The expression of long noncoding RNA NEAT1 is reduced in schizophrenia and modulates oligodendrocytes transcription. <i>NPJ Schizophrenia</i> , 2019, 5, 3.	3.6	44
26	Molecular signature of extracellular matrix pathology in schizophrenia. <i>European Journal of Neuroscience</i> , 2021, 53, 3960-3987.	2.6	42
27	Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes. <i>Schizophrenia Research</i> , 2011, 130, 238-249.	2.0	37
28	Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. <i>Neurobiology of Aging</i> , 2012, 33, 628.e1-628.e14.	3.1	32
29	Increased expression of RXR β in dementia: an early harbinger for the cholesterol dyshomeostasis?. <i>Molecular Neurodegeneration</i> , 2010, 5, 36.	10.8	29
30	CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 217-231.	0.8	28
31	Synaptic protein deficits are associated with dementia irrespective of extreme old age. <i>Neurobiology of Aging</i> , 2012, 33, 1125.e1-1125.e8.	3.1	26
32	Non-viability of crossing the Alzheimer mouse model Tg2576 with the type 2 diabetes mouse model ob/ob. <i>Neurobiology of Aging</i> , 2014, 35, e19-e20.	3.1	13
33	Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 565.	2.2	13
34	Microarray Database Mining and Cell Differentiation Defects in Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2011, 696, 67-74.	1.6	7
35	Comparison of brain connectomes by MRI and genomics and its implication in Alzheimer’s disease. <i>BMC Medicine</i> , 2020, 18, 23.	5.5	6
36	Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 7-19.	3.7	6

#	ARTICLE	IF	CITATIONS
37	Engagement of vascular early response genes typifies mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1357-1369.	0.8	5
38	Overexpression of Truncated Human DISC1 Induces Appearance of Hindbrain Oligodendroglia in the Forebrain During Development. <i>Schizophrenia Bulletin</i> , 2018, 44, 515-524.	4.3	3
39	[P2â€“107]: COMBINATION THERAPY OF TYPE 2 DIABETES MEDICATIONS AS A TREATMENT TARGET FOR ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P648.	0.8	1
40	O3-04-03: CROSS-TISSUE METHYLOMIC PROFILING IN ALZHEIMER'S DISEASE. , 2014, 10, P215-P215.		0
41	S4â€“02â€“03: Accelerating Medicines Partnership: Coâ€“Expression Networks. <i>Alzheimer's and Dementia</i> , 2016, 12, P322.	0.8	0